Company intelligence / Profile preview
Idorsia
Allschwil, Basel-Landschaft, Switzerlandidorsia.com ↗
- Ownership
- Public · IDIA
- Employees
- ~700
- Development stage
- Commercial
01
Overview
Idorsia has successfully commercialized several products including QUVIVIQ™ (daridorexant) for insomnia in the US and Europe; TRYVIO™/JERAYGO™ (aprocitentan) for resistant hypertension in the US/EU. Lucerastat for Fabry disease did not meet its Phase III primary endpoint but remains under open-label extension study with further regulatory discussions planned. The pipeline includes multiple programs at various stages from preclinical to proof-of-concept studies across CNS, cardiovascular, immunological disorders and rare diseases.
- Therapeutic areas
- PulmonologyRare DiseasesOtherPsychiatryDermatologyCardiovascularNeurologyInfectious Diseases
- Modalities
- Small molecules (primary)Synthetic glycan vaccines
- Industry
- Biotech
02
Drug pipeline
20 assets19 more assets in the full pipeline.
Request access →03
Partnerships
Global development/commercialization agreement with Viatris for selatogrel and cenerimod as of March 2024.
04
Financials
- Market cap
- $769M
- Total revenue
- $582K
- Enterprise value
- $332.6M
Beyond the preview
Go deeper on Idorsia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Idorsia.